MGMT and central nervous system cancer: This model predicted the grading as well as isocitrate dehydrogenase 1 and 2 (IDH1/2) mutation, O6-methylguanine-DNA methyltransferase (MGMT) methylation status, chromosomal regions 1p and 19q (1p19q) co-deletion, and loss of ATRX expression in cerebral gliomas with an overall good performance.31 However, the presence of a glioma had to be confirmed in all studies.